Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-27 10:03:45 - browse：221

A DNA helix, with dollar banknotes covering its strands, collapses next to another DNA helix with dollar banknotes strands — coverage from STAT — Adobe

The closely watched gene-editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with another biotech it partnered with to develop a potentially powerful new form of genome editing.

Prime and Myeloid Therapeutics, a startup co-founded by Pulitzer Prize-winning writer and cancer biologist Siddhartha Mukherjee, have filed competing arbitration claims over a deal they signed in March 2022.

Prime, spun out of the lab of Broad Institute biochemist David Liu, was built on technology for making small insertions, deletions, and single-letter changes in DNA. In theory, prime editing allows researchers to tackle the vast majority of disease-causing mutations, and the first treatments are already being readied for clinical trials. But it’s a poor fit in cases where hundreds or even thousands of different mutations in a long gene cause the same diseases, such as cystic fibrosis or Duchenne muscular dystrophy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout LOUD Podcast: Legal insider trading, booming biotech stocks

hotspot

WSS

Scientists unlock the key to scar

Bernie Sanders is gearing up to subpoena pharma CEOs

International team creates first chimeric human

Why you shouldn’t ask, “What country has the best health care?”

FogPharma raises $145 million in rare Series E round

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

leisure time

Wikipedia

focus

Duchenne breakthrough therapy leaves behind pioneering families

Philips to halt sales of sleep apnea machines in U.S.

Duchenne breakthrough therapy leaves behind pioneering families

Pfizer highlights cancer drugs it thinks could reignite investor interest

Hollywood unions extend contract negotiations for actors

RSV vaccines may be linked to small increased risk of developing GBS

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Pfizer highlights cancer drugs it thinks could reignite investor interest

Bright Health sells Medicare Advantage business to Molina

How to fix the rural physician shortage in the U.S.

hotspot

How generative AI ratchets up security threats for health systems

10 reasons why health care startups fail

House looks to weaken Medicare negotiation

How generative AI ratchets up security threats for health systems

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Merck, Johnson & Johnson CEOs will testify on high drug prices

knowledge

hotspot

explore

explore